Pharma Awards 2013

Emerging Entrepreneur of the Year (Mr.Vijay Kumar Ambati, President & CEO - CLEARSYNTH)
02-December-2013
Source: www.pharmabiz.com

With participation by over 900 companies from 95 countries, industry players from across the pharma industry congregated at CPhI/P-MEC India 2013 in Mumbai to explore India as destination for sourcing and consumption.

The three-day CPhI and P-MEC India 2013 was inaugurated today by Satej D Patil, MoS, Home (Urban & Rural), Food & Drug Administration. The event has participation from over 1000 plus exhibitors from 95 countries. All set to offer opportunities for moving up the Global Pharma value chain, the event is likely to be attended by nearly 30,000 delegates from 109 countries.

Mr.Vijay Kumar Ambati, Founder & CEO of Clearsynth Labs was awarded as the Emerging Entrepreneur of the Year at this event.

The mood at CPhI and P-MEC India 2013 was best articulated by Raghuveer Kini, executive director, Pharmexcil, when he quoted that "this is the on-ground manifestation of what several industry studies have been mentioning during last few months. Different studies report India's pharma sector to grow up to anywhere between $55 billion and $70 billion by the year 2020 at the CAGR between 14 per cent and 17 per cent. The future belongs to India in world pharma scenario. If you belong to the pharma industry anywhere in the world, you cannot ignore us now".

Desh Bandhu Gupta, chairman, Lupin Laboratories was awarded the Lifetime Achievement Award and Vijay Kumar Ambati from Clearsynth was conferred with Emerging Entrepreneur of the Year Award.

India's pharmaceutical industry is being touted as a key destination across its entire value chain for formulation, process development or packaging, the players in pharma machinery, technology, ingredients, outsourcing and biopharma segments look to opportunities in globalizing their businesses.

During the event, the industry participants are aiming to put their heads together to leverage India's strengths in moving up the value chain globally at a series of technical seminars and discussions which will be held onsite, over the 3 days of the event.

Speaking on the sidelines of the occasion, Joji George, managing director, UBM India highlighted the unprecedented interest on India by global pharma industry. He stated that, "It is no longer that India is considered as a mere destination of low-cost manufacturing and low-end bulk drugs. The profiles of international participants reflect that everyone from every known market across the globe is interested in India. Everyone is so keen to leverage CPhI and P-MEC India this year to grab the opportunity. It is the bus that no one wants to miss".

Indeed, the roster of participants reads like a 'who's who' list of global pharma industry. While the global pharma giants like BASF India, Capsugel Healthcare , Aurobindo Pharma, Merck Millipore, Indoco Remedies, ACG Worldwide, Bosch Ltd., Fette, IMA Industria Macchine Automatiche S.p.A, Marchesini Group, Truking Technology, Waters India, Agilent Technologies, Shimadzu, Thermo Fisher Scientific, Spinco Biotech, Waldner Laboreinrichtungen GmbH & Co. KG, Fabtech Technologies International Ltd., Mitsubishi Electric India, Cadmach Machinery Co. Pvt Ltd., Thermolab Scientific Equipments Pvt. Ltd., Hetero Drugs Ltd., UK Trade & Investment, DSM, Evonik Degussa India Pvt. Ltd. etc are present in full strength, there is participation from drug manufacturers, machinery manufacturers and importers from countries such as Ghana, Latvia, Afghanistan, Iraq, Burma, etc. High level delegations from Nepal, Vietnam, Sri Lanka, Korea, Turkey and Egypt are attending what would be the biggest gathering of pharma industry in this part of the world.

Earlier, in a glittering ceremony yesterday evening, the pharma fraternity recognised the talent and performances among its peers at Indian Pharma Awards. The awards were given in Operational Excellence, Excellence in Packaging Development, Excellence in Product Development, Excellence in Pharmaceutical Machinery/Equipment, Contract Research, CSR initiatives. The awards function culminated after declaring the Emerging Entrepreneur of the Year announcing the Lifetime Achievement award.

The evening also witnessed an intensive panel discussion on: "Moving up the Global Pharma Value Chain" where the panelists included industry stalwarts like S M Mudda, executive director-technical & operations, Micro Labs, Sudarashan Jain, managing director, Abbott India, Subodh Priolkar, regional managing director, Colorcon Asia and Dr P M Murali, president, ABLE (Association of Biotech Led Enterprises).

The reference for the world's research chemicals

02-Oct-2014
Source: Japan Times
As per article published in Japan Times

In Today's virtual global economy, most of the people already have go to sites for an entire range of need and desire, from media to food, all accessible from their screens. One enterprising Indian company has made ordering chemical compounds for researchers from kyoto to Kampala just as easy as, under its guiding vision: "The catalyst is making your research work."

"People go to Google when they need information," say Vijay Kumar Ambati, president and CEO of Clearsynth. "A book seeker goes to Amazon. Similarly we want researcher to access Clearsynth for their needs." Already, the technology based research-driven company has created the world largest inventory of over 359,000 refrence and research chemicals: globally available on click of a mouse.

It's ambitious goal of the company that will only turn in next five years. "I saw there was an opportunity high end research chemicals that scientist need to accelerate their work," he say, recalling the conception of Clearsynth after amassing more than 20 years of experience in pharmaceutical sector.

"I realized that we had this potential in India, and a bulb lit up."

The idea becomes a successful business that has more than doubled each year since 2010, and was rated an Outstanding SME in 2013 CIRSIL, the leading Indian rating agency.

Based in Mumbai, ISO-certified Clearsynth has located its main laboratory and R&D center in Hyderabad. It's near the Indian Institute of Chemical Technology, which provides a talented pool of India's best chemist for a growth oriented company that expects to hire up to 100 new scientist each year in the next three. A second R&D centre is located in San Diego in the U.S., and laboratory planned in Canada.

"The five next years will be very important for us, especially in Japan a key market," comment Ambati. "Just this year, we plan to increase our business there y more than 200 percent. "Working through its Japanese distributor, Toyo Science, Clearsynth already supplies researcher in Tokyo university and Osaka university.

He remembers his first visit to Japan in 1995: "I got out in Osaka, went to the bus-stop and read a sign that says: 'The bus stops here, not time.' The bus had not been late a single time in last 10 years. It was mind blowing."

Today he knows what the Japanese market demand. "Japanese are also the strictest of all about quality and also value long term relationships. Catering to the market, with its stringent standards and timely delivery expectations, make us the world-class organization"

To date, Clearsynth has not received any quality complaints from the Japanese clients, and not a single return. It's implementation plan Japan next year includes: setting a single point of contact and a stocking point for orders, including products specifically for the Japanese market; working more closely with distributors; providing labelling, literature and local language support in Japanese; and basing a dedicated Clearsynth technical-marketing specialist in Japan to support its distributors.

"We have a long way to go," Ambati concludes. From developing innovative Swiss and Swedish made packaging that securely deliver tiny amounts to providing the 10 percent of its inventory that no other company in the world can supply. Clearsynth is already leading in its niche. "Our goal will inspire us to reach as far as we can."

Brand Equity Lessons At CPhI Worldwide From "Rx India"

16-Oct-2014
Source: http://www.outsourcedpharma.com
By Louis Garguilo,
Executive Editor,
Outsourced Pharma

Six exhibition halls in Paris Nord Villepinte, France, encased city-like ecosystems (or gigantic beehives); the conference in total so big it was hard to plan a strategy. It was a battle of outsourcing provider brands, and differentiation was difficult.

The lead sponsor's brand has been under attack. Some say it is "about time" and fixes necessary, others see discourse denigrating to a degree of "finger-pointing."

The conference (CPhI Worldwide 2014) and brand (India's pharma/outsourcing industry) coalesced in a seamless marketing integration. With a pleasing yellow-orange sunrise background supporting a light font and professional logo (Rx India), the chosen message blanketed the convention, covering it entirely but softly. It flowed on strategically placed banners, decorated pillars and hosted crossbeams upon entrance and egress.

The campaign was in effect a defense, a rebuttal. But like the art of aikido, it defended-and counter-attacked-by deftly redirecting the negative energy. It supplanted a recent focus on quality issues-US FDA issued import alerts against 21 Indian manufacturing facilities during 2013-with industry-based statistics intended to both inform and build reputation. The content was not so much marketing copy par excellence as a quiet, nearly subliminal, data articulation:

• 523 Indian facilities are registered with US FDA, the highest number for any country outside the US.
• Indian companies accounted for 39% of all Abbreviated New Drug Application (ANDA) approvals in 2013.
• India accounted for 40% by volume of US generic drug imports in 2013.

This initiative provides universal instruction in brand equity building, maintenance and support. It is fronted by a group established by the national government known as the India Brand Equity Foundation (IBEF).

I had the opportunity to speak privately to the CEO of IBEF, Ms. Aparna Dutt Sharma. She was relaxed and determined, like the campaign she was overseeing at CPhI, and said such things as, "We're not really interested in dwelling on recent discussions. We're moving the conversation to facts of an established industry primacy, and the positive influence on the future of the industry we are bringing. India is helping to advance the science and technology of the industry. That is the message"

Cushman & Wakefield, featuring our Canadian Lab operations!

August 11, 2015
Source: http://www.flipdocs.com/showbook.aspx?ID=10007901_908115&P=2

By Randolph W. Borron,
Vice Chairman & Canadian Lead,
Life Science Practice Group,
Cushman & Wakefield

CLEARSYNTH OPENS LAB IN MISSISSAUGA

Clearsynth is a technology based research driven enterprise, offering integrated products and services in Reference Standards; Stable Isotope Labeled Compounds, Metabolites, Impurities, Chiral Compounds and other related products. Currently headquartered in Mumbai, India, with its laboratory in Hyderabad, Clearsynth was seeking to set up a base for its North American operations in Canada.

C&W was tasked with surveying the market, touring, and drafting and executing an offer within Clearsynth's executives' four-day visit to Toronto. C&W conducted a thorough search throughout the GTA to find a specialized high quality lab space in move-in condition. The team was able to find three suitable options and managed to secure a fully built wet laboratory, requiring minimal additional capital expenditures by Clearsynth. They have now commenced their operations in a perfectly suited facility in the Sheridan Park area and have started to build their existing teams in marketing, operations and synthesis and welcome any referrals/support.